Drug Development

Jazz Pharma's lung cancer drug Zepzelca fails a key trial, raising regulatory questions. Yet its strength in another setting reveals a complex drug development system.

MBX Biosciences' new one-year data for canvuparatide isn't just a clinical win; it's a calculated move to dominate a billion-dollar market left vacant.

Novartis unveils groundbreaking Phase III data for Rhapsido, offering hope as the first potential targeted therapy for 29 million chronic hive sufferers.

For decades, patients with a rare autoimmune anemia faced a cycle of steroids and relapse. New data on a targeted therapy may finally offer a durable solution.

Xeris Biopharma secures a new patent for its rare disease drug KEVEYIS until 2039, a strategic move to fend off generic competition and lock in revenue.

Amedea Pharma's Medical Innovation Olympics isn't just a contest; it's a data-driven crucible for new treatments, with longevity medicine taking center stage.

A projected 14.9% CAGR signals a gold rush in Alzheimer's agitation treatment. New, safer drugs are replacing risky antipsychotics, offering hope to millions.

With a promising cancer therapy but precarious finances, Propanc Biopharma's stock buyback raises a critical question: is it a sign of confidence or a high-stakes gamble?

Sweeping data from EHA 2026 shows Syndax's Revuforj achieving remarkable success across leukemia settings, signaling a new standard of care and a major market coup.

Stunning head-to-head trial data shows Takeda's zasocitinib is 2.5x more effective than its rival, signaling a major market disruption and validating a landmark deal.

New data on an all-oral combo therapy for AML shows remarkable efficacy, offering new hope for patients and cementing Syndax's competitive advantage.

Relmada Therapeutics poaches a Sage neurosteroid expert for its sepranolone program. A look at the strategic rationale behind a move that signals big ambitions.

Hyundai Bioscience offers a free drug for an untreatable Ebola strain. It's a bold humanitarian gesture, and a masterclass in strategic maneuvering.

Cytovance Biologics' new cell line service boasts top-tier yields. This strategic shift toward a 'one-stop-shop' model could redefine speed and cost in biopharma.

With its pivotal Phase 3 trial complete, Rafael Holdings is on a path to redefine treatment for NPC and transform itself into a commercial-stage biotech.

Health Canada's Priority Review for a new Duchenne muscular dystrophy drug signals hope for patients and a strategic test of Canada's rare disease market.

A groundbreaking partnership between Servier and n-Lorem Foundation blends pharma R&D muscle with non-profit agility to develop ASO therapies for the rarest of diseases.

Sanofi's promising nerve disease drug fails in late-stage trials, leaving vulnerable patients in limbo and highlighting the brutal realities of medical innovation.

Takeda seeks FDA approval for its gut-focused drug ENTYVIO in children, a major step toward a new era of treatment for the rising tide of pediatric IBD.

A novel TYK2 inhibitor that can enter the central nervous system has begun human trials, signaling a new frontier for treating diseases like MS and lupus.